Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis

Ionis and AstraZeneca's eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for co-primary and secondary endpoints at 35 weeks compared to the external placebo group Eplontersen achieved an 81.2% reduction in the co-primary endpoint of serum transthyretin (TTR) concentration from baseline, demonstrating reduced TTR protein production Eplontersen demonstrated a favorable safety and tolerability profile CARLSBAD, Calif., Sept. 7, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a planned 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). In the study, eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for its co-primary and secondary efficacy endpoints compared to the external placebo group. Eplontersen demonstrated a favorable safety and tolerability profile. The study results were presented today at the International Symposium on Amyloidosis (ISA) in Heidelberg, Germany.

The release as fetched from its publisher. ionis.com ↗